8-K
filed April 18, 2024, 7:59 PM ET
ticker OCUL
CIK 0001393434
leadership
confidence high
sentiment neutral
materiality 0.65
Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased
OCULAR THERAPEUTIX, INC
- Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.
- Prior CEO Antony C. Mattessich resigned; severance includes 24 months base salary and 24-month equity acceleration.
- Nadia Waheed appointed Chief Medical Officer effective May 20, 2024, replacing Rabia Gurses Ozden.
- 2019 Inducement Stock Incentive Plan amended to increase shares from 3,804,000 to 4,804,000.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pravin U. Dugel, M.D. was appointed as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Antony C. Mattessich resigned as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rabia Gurses Ozden, M.D. departed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
- Action
- ceased
- Role
- Chief Medical Officer
Exact text from the filing
Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nadia Waheed, M.D. was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.